Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.65 |
| ▸ | NAAA | Q02083 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.52 |
| ▸ | PPID | Q08752 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22851911 | 0.97 | NPC1 (0.70) | NPC1TDP1NAAAPOLBPPID | |
| SCHEMBL16679367 | 0.95 | NPC1 (0.68) | NPC1TDP1NAAAPOLBPPID | |
| SCHEMBL6966882 | 0.87 | NPC1 (0.57) | NPC1TDP1NAAAPPID | |
| SCHEMBL8391980 | 0.85 | FKBP1A (0.72) | NPC1TDP1NAAAFKBP1A | |
| SCHEMBL3141502 | 0.85 | FKBP1A (0.52) | NPC1TDP1NAAAPOLBFKBP1A | |
| SCHEMBL9556740 | 0.85 | NPC1 (0.51) | NPC1TDP1NAAAPOLBFKBP1A | |
| SCHEMBL25432319 | 0.82 | NPC1 (0.93) | NPC1TDP1NAAAPOLBFKBP1A | |
| SCHEMBL23095801 | 0.82 | SMN1; SMN2 (0.62) | NPC1POLBPPID | |
| SCHEMBL14100159 | 0.82 | TSHR (0.72) | NPC1TDP1NAAAFKBP1AGAA | |
| SCHEMBL9557017 | 0.80 | DPP4 (0.52) | NPC1TDP1NAAAPOLBFKBP1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8722622-B2 | FGF21 conjugates and anti-diabetic uses thereof | COVX TECHNOLOGIES IRELAND, LIMITED (IE) | 2014-05-13 | — | — | US | disclosed |
| US-8722622-B2 | FGF21 conjugates and anti-diabetic uses thereof | COVX TECHNOLOGIES IRELAND, LIMITED (IE) | 2014-05-13 | — | — | US | disclosed |
| US-20120282279-A1 | Anti-Diabetic Compounds | COVX TECHNOLOGIES IRELAND LIMITED (IE) | 2012-11-08 | — | — | US | disclosed |
| US-20120282279-A1 | Anti-Diabetic Compounds | COVX TECHNOLOGIES IRELAND LIMITED (IE) | 2012-11-08 | — | — | US | disclosed |
| WO-2012059873-A2 | ANTI-DIABETIC COMPOUNDS | COVX TECHNOLOGIES IRELAND, LTD. (IE) | 2012-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120282279-A1 | Anti-Diabetic Compounds | GLP1R, FGF2, FGFR1 | NPC1 2418/4885TDP1 4429/4885NAAA 1593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.